Take off with Allarity Therapeutics Inc. (ALLR): Get ready for trading

Allarity Therapeutics Inc. (NASDAQ: ALLR) stock fell -18.40% on Tuesday to $0.24 against a previous-day closing price of $0.29. With 7.2 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.84 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.2750 whereas the lowest price it dropped to was $0.2320. The 52-week range on ALLR shows that it touched its highest point at $9.67 and its lowest point at $0.20 during that stretch.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ALLR was up-trending over the past week, with a rise of 2.52%, but this was down by -6.00% over a month. Three-month performance dropped to -67.58% while six-month performance fell -77.99%. The stock lost -96.99% in the past year, while it has lost -18.35% so far this year. A look at the trailing 12-month EPS for ALLR yields -4.58 with Next year EPS estimates of -1.55. For the next quarter, that number is -0.42. This implies an EPS growth rate of -412.60% for this year and 28.60% for next year.

Float and Shares Shorts:

At present, 9.87 million ALLR shares are outstanding with a float of 8.41 million shares on hand for trading. On Dec 29, 2022, short shares totaled 0.16 million, which was 1.08% higher than short shares on Nov 29, 2022. In addition to Mr. James G. Cullem J.D. as the firm’s Interim CEO, Chief Bus. Officer, Sr. VP of Corp. Devel. & Director, Dr. Marie Foegh DrSc, M.D. serves as its Chief Medical Officer.


Institutional Ownership:

Through their ownership of 0.94% of ALLR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 0.78% of ALLR, in contrast to 0.37% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in ALLR with 0.32% of the stake, LMR Partners LLP holds 46,033 shares worth 46,033. A second-largest stockholder of ALLR, Geode Capital Management LLC, holds 29,433 shares, controlling over 0.20% of the firm’s shares. Renaissance Technologies LLC is the third largest shareholder in ALLR, holding 25,286 shares or 0.18% stake. With a 0.14% stake in ALLR, the Bridgeway Ultra Small Company Mar is the largest stakeholder. A total of 20,000 shares are owned by the mutual fund manager. The Fidelity Series Total Market Inde, which owns about 0.10% of ALLR stock, is the second-largest Mutual Fund holder. It holds 14,501 shares valued at 4263.0. Fidelity Extended Market Index Fu holds 0.08% of the stake in ALLR, owning 11,267 shares worth 3312.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, ALLR reported revenue of $0.00 and operating income of -$4.84M. The EBITDA in the recently reported quarter was -$4.81M and diluted EPS was -$0.52.


Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ALLR since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ALLR analysts setting a high price target of $8.00 and a low target of $8.00, the average target price over the next 12 months is $8.00. Based on these targets, ALLR could surge 3233.33% to reach the target high and rise by 3233.33% to reach the target low. Reaching the average price target will result in a growth of 3233.33% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ALLR will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of -$2.17 being high and -$2.17 being low. For ALLR, this leads to a yearly average estimate of -$2.17. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Allarity Therapeutics Inc. surprised analysts by -$0.43 when it reported -$0.68 EPS against a consensus estimate of -$0.25. The surprise factor in the prior quarter was -$0.10. Based on analyst estimates, the high estimate for the next quarter is -$0.42 and the low estimate is -$0.42. The average estimate for the next quarter is thus -$0.42.

Leave a Comment

Your email address will not be published. Required fields are marked *